Mometasone Furoate Alissa Healthcare Research (Mometasone Furoate Monohydrate)

Mometasone furoate is a topical nasal corticosteroid that reduces inflammation in the upper airway. It is indicated for the following conditions:

• Allergic rhinitis: relief of nasal congestion, itching, and sneezing caused by seasonal or perennial allergens.
• Seasonal allergic rhinitis: control of symptoms during pollen seasons.
• Nasal polyps: reduction of polyp size and improvement of nasal airflow.

• Mometasone furoate binds to intracellular glucocorticoid receptors in nasal mucosal cells, forming a complex that translocates to the nucleus and inhibits transcription of pro‑inflammatory cytokines. This action reduces inflammatory cell migration, edema, and mucus production, leading to decreased nasal inflammation and symptom relief.

Mometasone furoate may cause local and systemic adverse reactions. Most are mild and reversible.

Common Side Effects

• Nasal irritation or burning sensation.
• Headache.
• Epistaxis (nosebleed).
• Altered taste or bitter taste.
• Throat irritation or cough.
• Dryness of nasal passages.

Serious or Rare Side Effects

• Nasal septal perforation.
• Severe allergic reaction (anaphylaxis).
• Vision changes or cataract formation.
• Adrenal suppression with prolonged high‑dose use.
• Opportunistic fungal infection of the nasal cavity.
• Elevated intra‑ocular pressure or glaucoma exacerbation.

Before initiating therapy, consider the following safety measures:

• Assess for active nasal or sinus infections: avoid use until infection resolves.
• Use the lowest effective dose: limit duration to the prescribed period.
• Monitor for signs of adrenal suppression: especially with long‑term or high‑dose therapy.
• Caution in patients with glaucoma or cataracts: monitor intra‑ocular pressure.
• Avoid use in children under two years of age unless specifically prescribed.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mometasone furoate can interact with other medications that affect corticosteroid metabolism or systemic exposure.

Major Interactions (Avoid)

• Systemic corticosteroids: additive immunosuppression and adrenal effects.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase local steroid levels.
• Nasal decongestant sprays used concurrently: risk of mucosal irritation.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise exposure.
• Antifungal agents (e.g., fluconazole): monitor for increased local effects.